Sugi Predict

Sugi Predict / Compounds / SCHEMBL67885

SCHEMBL67885

SCHEMBL67885

NCCNC(=O)C(F)(F)F

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.65
▸ SMN1; SMN2 Q16637 2/20 0.65
▸ POLB P06746 1/20 0.65
▸ MEN1 O00255 1/20 0.62
▸ KMT2A Q03164 1/20 0.62
▸ CA3 P07451 2/20 0.56
▸ CA5A P35218 2/20 0.56
▸ CA5B Q9Y2D0 2/20 0.56
▸ CA2 P00918 2/20 0.56
▸ CA14 Q9ULX7 2/20 0.56
▸ CA12 O43570 1/20 0.56
▸ CA4 P22748 1/20 0.56
▸ CA6 P23280 1/20 0.56
▸ CA7 P43166 1/20 0.56
▸ CA9 Q16790 1/20 0.56
▸ EPHX1 P07099 1/20 0.52
▸ HDAC6 Q9UBN7 1/20 0.38
▸ HPGD P15428 2/20 0.38
▸ GLA P06280 1/20 0.38
▸ ALOX12 P18054 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5407882 0.98 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
Trifluoroacetic Acid SCHEMBL17747121 0.93 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL8041559 0.87 CA5B (0.77) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL10232648 0.87 CA5B (0.77) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL3149189 0.86 ALDH1A1 (0.74) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
Hydrochloric Acid SCHEMBL29241548 0.84 SMN1; SMN2 (0.71) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL6490885 0.84 ALDH1A1 (0.78) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL13861685 0.84 ALDH1A1 (0.79) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
SCHEMBL5367616 0.82 MEN1 (0.79) ALDH1A1SMN1; SMN2POLBMEN1KMT2A
Hydrochloric Acid SCHEMBL29241679 0.82 SMN1; SMN2 (0.75) ALDH1A1SMN1; SMN2POLBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113527312-B Green synthesis method of sitagliptin intermediate 江苏八巨药业有限公司 2022-06-07 — — CN claimed
CN-113527312-A Green synthesis method of sitagliptin intermediate 江苏八巨药业有限公司 2021-10-22 — — CN claimed
EP-2670750-B1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR FIBROGEN INC (US) 2016-09-14 — — EP claimed
US-9271970-B2 Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase FIBROGEN, INC. (US) 2016-03-01 — — US claimed
US-20150174110-A1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE FIBROGEN, INC. 2015-06-25 — — US claimed
US-8921389-B2 Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase FIBROGEN, INC. (US) 2014-12-30 — — US claimed
US-20140088101-A1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE FIBROGEN, INC. (US) 2014-03-27 — — US claimed
EP-2670750-A1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE Fibrogen, Inc. (US) 2013-12-11 — — EP claimed
WO-2012106472-A1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE FIBROGEN, INC. (US) 2012-08-09 — — WO claimed
CN-1606439-A Cis-imidazolines HOFFMANN LA ROCHE (CH) 2005-04-13 — — CN claimed
EP-0736035-A4 PRETARGETING METHODS AND COMPOUNDS NEORX CORP (US) 1999-09-01 — — EP claimed
EP-0736035-A1 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1996-10-09 — — EP claimed
WO-1995015335-A2 PRETARGETING METHODS AND COMPOUNDS NEORX CORPORATION (US) 1995-06-08 — — WO claimed
US-12595508-B2 Nucleotide cleavable linkers and uses thereof Singular Genomics Systems, Inc. (US) 2026-04-07 — — US disclosed
EP-4714951-A1 FLUORESCENT DYE, SYNTHESIS THEREFOR AND USE THEREOF MGI Tech Co., Ltd. (CN) 2026-03-25 — — EP disclosed
US-12577271-B2 Modified nucleotides and uses thereof Singular Genomics Systems, Inc. (US) 2026-03-17 — — US disclosed
US-4137234-A ANTIHISTAMINES SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) 1979-01-30 — — US disclosed
US-4018931-A INHIBITION OF H-2 HISTAMINE RECEPTORS SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1977-04-19 — — US disclosed
US-4018928-A INHIBITORS OF H-2 HISTAMINE RECEPTORS SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1977-04-19 — — US disclosed
US-3950353-A HISTAMINE INHIBITORS SMITH KLINE & FRENCH LABORATORIES LIMITED (EN) 1976-04-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12595508-B2 Nucleotide cleavable linkers and uses thereof NSUN2, CCRL2, NOP2 ALDH1A1 3274/4885SMN1; SMN2 1706/4885POLB 160/4885
US-12577271-B2 Modified nucleotides and uses thereof NUDT1, NSUN2, CCRL2 ALDH1A1 2320/4885SMN1; SMN2 2427/4885POLB 35/4885
US-20150174110-A1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE HIF1AN, HIF1A, EGLN2 ALDH1A1 660/4885SMN1; SMN2 4317/4885POLB 496/4885
US-20140088101-A1 NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE HIF1AN, HIF1A, EGLN2 ALDH1A1 660/4885SMN1; SMN2 4317/4885POLB 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.